Preliminary findings based on analysis of data from more than 20,000 participants
Russia’s Sputnik V vaccine has 91.6% efficacy against symptomatic coronavirus, interim trial results have suggested.
The preliminary findings are based on analysis of data from more than 20,000, mostly white, participants, three-quarters of whom received the vaccine. The remainder received a placebo.
